Global G-CSF Biosimilars Market Growth 2024-2030

Publication ID:

LPI12249275

Publication Date:

December 13, 2024

Pages:

113

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global G-CSF Biosimilars market size was valued at US$ million in 2023. With growing demand in downstream market, the G-CSF Biosimilars is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global G-CSF Biosimilars market. G-CSF Biosimilars are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of G-CSF Biosimilars. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the G-CSF Biosimilars market.
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on G-CSF Biosimilars market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the G-CSF Biosimilars market. It may include historical data, market segmentation by Type (e.g., Human Growth Hormone, Erythropoietin), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the G-CSF Biosimilars market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the G-CSF Biosimilars market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the G-CSF Biosimilars industry. This include advancements in G-CSF Biosimilars technology, G-CSF Biosimilars new entrants, G-CSF Biosimilars new investment, and other innovations that are shaping the future of G-CSF Biosimilars.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the G-CSF Biosimilars market. It includes factors influencing customer ' purchasing decisions, preferences for G-CSF Biosimilars product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the G-CSF Biosimilars market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting G-CSF Biosimilars market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the G-CSF Biosimilars market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the G-CSF Biosimilars industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the G-CSF Biosimilars market.
Market Segmentation:
G-CSF Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Segmentation by application
Blood Disorders
Oncology Diseases
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Roche
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Key Questions Addressed in this Report
What is the 10-year outlook for the global G-CSF Biosimilars market?
What factors are driving G-CSF Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do G-CSF Biosimilars market opportunities vary by end market size?
How does G-CSF Biosimilars break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global G-CSF Biosimilars Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for G-CSF Biosimilars by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for G-CSF Biosimilars by Country/Region, 2019, 2023 & 2030
2.2 G-CSF Biosimilars Segment by Type
2.2.1 Human Growth Hormone
2.2.2 Erythropoietin
2.2.3 Monoclonal Antibodies
2.2.4 Insulin
2.2.5 Interferon
2.2.6 Granulocyte-Colony Stimulating Factor
2.3 G-CSF Biosimilars Sales by Type
2.3.1 Global G-CSF Biosimilars Sales Market Share by Type (2019-2024)
2.3.2 Global G-CSF Biosimilars Revenue and Market Share by Type (2019-2024)
2.3.3 Global G-CSF Biosimilars Sale Price by Type (2019-2024)
2.4 G-CSF Biosimilars Segment by Application
2.4.1 Blood Disorders
2.4.2 Oncology Diseases
2.4.3 Chronic And Autoimmune Diseases
2.4.4 Growth Hormone Deficiencies
2.5 G-CSF Biosimilars Sales by Application
2.5.1 Global G-CSF Biosimilars Sale Market Share by Application (2019-2024)
2.5.2 Global G-CSF Biosimilars Revenue and Market Share by Application (2019-2024)
2.5.3 Global G-CSF Biosimilars Sale Price by Application (2019-2024)
3 Global G-CSF Biosimilars by Company
3.1 Global G-CSF Biosimilars Breakdown Data by Company
3.1.1 Global G-CSF Biosimilars Annual Sales by Company (2019-2024)
3.1.2 Global G-CSF Biosimilars Sales Market Share by Company (2019-2024)
3.2 Global G-CSF Biosimilars Annual Revenue by Company (2019-2024)
3.2.1 Global G-CSF Biosimilars Revenue by Company (2019-2024)
3.2.2 Global G-CSF Biosimilars Revenue Market Share by Company (2019-2024)
3.3 Global G-CSF Biosimilars Sale Price by Company
3.4 Key Manufacturers G-CSF Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers G-CSF Biosimilars Product Location Distribution
3.4.2 Players G-CSF Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for G-CSF Biosimilars by Geographic Region
4.1 World Historic G-CSF Biosimilars Market Size by Geographic Region (2019-2024)
4.1.1 Global G-CSF Biosimilars Annual Sales by Geographic Region (2019-2024)
4.1.2 Global G-CSF Biosimilars Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic G-CSF Biosimilars Market Size by Country/Region (2019-2024)
4.2.1 Global G-CSF Biosimilars Annual Sales by Country/Region (2019-2024)
4.2.2 Global G-CSF Biosimilars Annual Revenue by Country/Region (2019-2024)
4.3 Americas G-CSF Biosimilars Sales Growth
4.4 APAC G-CSF Biosimilars Sales Growth
4.5 Europe G-CSF Biosimilars Sales Growth
4.6 Middle East & Africa G-CSF Biosimilars Sales Growth
5 Americas
5.1 Americas G-CSF Biosimilars Sales by Country
5.1.1 Americas G-CSF Biosimilars Sales by Country (2019-2024)
5.1.2 Americas G-CSF Biosimilars Revenue by Country (2019-2024)
5.2 Americas G-CSF Biosimilars Sales by Type
5.3 Americas G-CSF Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC G-CSF Biosimilars Sales by Region
6.1.1 APAC G-CSF Biosimilars Sales by Region (2019-2024)
6.1.2 APAC G-CSF Biosimilars Revenue by Region (2019-2024)
6.2 APAC G-CSF Biosimilars Sales by Type
6.3 APAC G-CSF Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe G-CSF Biosimilars by Country
7.1.1 Europe G-CSF Biosimilars Sales by Country (2019-2024)
7.1.2 Europe G-CSF Biosimilars Revenue by Country (2019-2024)
7.2 Europe G-CSF Biosimilars Sales by Type
7.3 Europe G-CSF Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa G-CSF Biosimilars by Country
8.1.1 Middle East & Africa G-CSF Biosimilars Sales by Country (2019-2024)
8.1.2 Middle East & Africa G-CSF Biosimilars Revenue by Country (2019-2024)
8.2 Middle East & Africa G-CSF Biosimilars Sales by Type
8.3 Middle East & Africa G-CSF Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of G-CSF Biosimilars
10.3 Manufacturing Process Analysis of G-CSF Biosimilars
10.4 Industry Chain Structure of G-CSF Biosimilars
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 G-CSF Biosimilars Distributors
11.3 G-CSF Biosimilars Customer
12 World Forecast Review for G-CSF Biosimilars by Geographic Region
12.1 Global G-CSF Biosimilars Market Size Forecast by Region
12.1.1 Global G-CSF Biosimilars Forecast by Region (2025-2030)
12.1.2 Global G-CSF Biosimilars Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global G-CSF Biosimilars Forecast by Type
12.7 Global G-CSF Biosimilars Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer G-CSF Biosimilars Product Portfolios and Specifications
13.1.3 Pfizer G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis G-CSF Biosimilars Product Portfolios and Specifications
13.2.3 Novartis G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche G-CSF Biosimilars Product Portfolios and Specifications
13.3.3 Roche G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Merck & Co.
13.4.1 Merck & Co. Company Information
13.4.2 Merck & Co. G-CSF Biosimilars Product Portfolios and Specifications
13.4.3 Merck & Co. G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck & Co. Main Business Overview
13.4.5 Merck & Co. Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi G-CSF Biosimilars Product Portfolios and Specifications
13.5.3 Sanofi G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson G-CSF Biosimilars Product Portfolios and Specifications
13.6.3 Johnson & Johnson G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Gilead Science
13.7.1 Gilead Science Company Information
13.7.2 Gilead Science G-CSF Biosimilars Product Portfolios and Specifications
13.7.3 Gilead Science G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Gilead Science Main Business Overview
13.7.5 Gilead Science Latest Developments
13.8 GlaxoSmithKline
13.8.1 GlaxoSmithKline Company Information
13.8.2 GlaxoSmithKline G-CSF Biosimilars Product Portfolios and Specifications
13.8.3 GlaxoSmithKline G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 GlaxoSmithKline Main Business Overview
13.8.5 GlaxoSmithKline Latest Developments
13.9 AbbVie
13.9.1 AbbVie Company Information
13.9.2 AbbVie G-CSF Biosimilars Product Portfolios and Specifications
13.9.3 AbbVie G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 AbbVie Main Business Overview
13.9.5 AbbVie Latest Developments
13.10 Amgen
13.10.1 Amgen Company Information
13.10.2 Amgen G-CSF Biosimilars Product Portfolios and Specifications
13.10.3 Amgen G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Amgen Main Business Overview
13.10.5 Amgen Latest Developments
13.11 AstraZeneca
13.11.1 AstraZeneca Company Information
13.11.2 AstraZeneca G-CSF Biosimilars Product Portfolios and Specifications
13.11.3 AstraZeneca G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 AstraZeneca Main Business Overview
13.11.5 AstraZeneca Latest Developments
13.12 Bayer
13.12.1 Bayer Company Information
13.12.2 Bayer G-CSF Biosimilars Product Portfolios and Specifications
13.12.3 Bayer G-CSF Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Bayer Main Business Overview
13.12.5 Bayer Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂